Overall, the results highlight the potential of compound 12 as a promising candidate for further development as an anticancer agent, particularly in cancers where HER2 and JNK1 are dysregulated, such as breast and colon cancer [26]. The gene discussed is ERBB2; the disease is malignant colon neoplasm.